Advertisement

Advertisement

DNLI Stock Latest News

Denali Therapeutics price target raised to $35 from $30 at B. Riley

The FlyDenali Therapeutics price target raised to $35 from $30 at B. Riley

Denali’s DNL921 Trial: Early Alzheimer’s Safety Data That Could Shape Long-Term Upside

PremiumCompany Announcements

Denali’s DNL921 Trial: Early Alzheimer’s Safety Data That Could Shape Long-Term Upside

18d ago

Denali Therapeutics’ AVLAYAH Launch Reshapes Earnings Story

PremiumCompany Announcements

Denali Therapeutics’ AVLAYAH Launch Reshapes Earnings Story

19d ago

Analyst Reiterates Buy on Denali Therapeutics as AVLAYAH Launch Gains Traction and Alzheimer’s Pipeline Advances; $42 Price Target Maintained

PremiumRatings

Analyst Reiterates Buy on Denali Therapeutics as AVLAYAH Launch Gains Traction and Alzheimer’s Pipeline Advances; $42 Price Target Maintained

1M ago

Denali Therapeutics price target raised to $40 from $36 at Morgan Stanley

PremiumThe Fly

Denali Therapeutics price target raised to $40 from $36 at Morgan Stanley

1M ago

Denali Therapeutics price target raised to $34 from $25 at UBS

PremiumThe FlyDenali Therapeutics price target raised to $34 from $25 at UBS

1M ago

Denali Therapeutics price target raised to $34 from $31 at Baird

The Fly

Denali Therapeutics price target raised to $34 from $31 at Baird

1M ago

Denali Therapeutics reports Q2 EPS (68c), consensus (47c)

The Fly

Denali Therapeutics reports Q2 EPS (68c), consensus (47c)

1M ago

Denali Therapeutics treatment of frontotemporal dementia granted orphan status

PremiumThe Fly

Denali Therapeutics treatment of frontotemporal dementia granted orphan status

1M ago

Denali Therapeutics Sells Priority Review Voucher for Capital

PremiumCompany Announcements

Denali Therapeutics Sells Priority Review Voucher for Capital

1M ago

Denali Therapeutics price target raised to $36 from $35 at Morgan Stanley

PremiumThe Fly

Denali Therapeutics price target raised to $36 from $35 at Morgan Stanley

2M ago

Denali Therapeutics price target raised to $35 from $31 at Deutsche Bank

PremiumThe Fly

Denali Therapeutics price target raised to $35 from $31 at Deutsche Bank

2M ago

Denali Therapeutics falls -14.1%

PremiumThe FlyDenali Therapeutics falls -14.1%

2M ago

Denali Therapeutics falls -12.4%

The Fly

Denali Therapeutics falls -12.4%

2M ago

Denali Therapeutics price target raised to $26 from $20 at Wedbush

The Fly

Denali Therapeutics price target raised to $26 from $20 at Wedbush

2M ago

Denali Therapeutics resumed with an Overweight at JPMorgan

PremiumThe Fly

Denali Therapeutics resumed with an Overweight at JPMorgan

2M ago

Denali’s New Pompe Disease Trial Adds Depth to Its Rare Disease Pipeline

PremiumCompany Announcements

Denali’s New Pompe Disease Trial Adds Depth to Its Rare Disease Pipeline

2M ago

Denali Monetizes FDA Voucher to Advance CNS Pipeline

PremiumCompany Announcements

Denali Monetizes FDA Voucher to Advance CNS Pipeline

3M ago

Denali Therapeutics enters agreement to sell Rare Pediatric Disease PRV

PremiumThe Fly

Denali Therapeutics enters agreement to sell Rare Pediatric Disease PRV

3M ago

Denali Therapeutics Shareholders Back Board, Auditors, Executive Pay

PremiumCompany AnnouncementsDenali Therapeutics Shareholders Back Board, Auditors, Executive Pay

3M ago

Biogen and Denali’s BIIB122 Parkinson’s Trial Completion Sets Up Key Catalyst for Investors

Company Announcements

Biogen and Denali’s BIIB122 Parkinson’s Trial Completion Sets Up Key Catalyst for Investors

3M ago

Denali Therapeutics price target lowered to $35 from $40 at Morgan Stanley

The Fly

Denali Therapeutics price target lowered to $35 from $40 at Morgan Stanley

4M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >